Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Capital Expenditures (2023 - 2025)

Historic Capital Expenditures for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q3 2025 value amounting to $600000.0.

  • Artiva Biotherapeutics' Capital Expenditures rose 52500.0% to $600000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 8369.03%. This contributed to the annual value of $642000.0 for FY2024, which is 8029.47% down from last year.
  • Per Artiva Biotherapeutics' latest filing, its Capital Expenditures stood at $600000.0 for Q3 2025, which was up 52500.0% from $684000.0 recorded in Q2 2025.
  • In the past 5 years, Artiva Biotherapeutics' Capital Expenditures registered a high of $882000.0 during Q1 2025, and its lowest value of $18000.0 during Q1 2024.
  • Moreover, its 3-year median value for Capital Expenditures was $464000.0 (2024), whereas its average is $402555.6.
  • Its Capital Expenditures has fluctuated over the past 5 years, first crashed by 8993.71% in 2024, then skyrocketed by 480000.0% in 2025.
  • Over the past 3 years, Artiva Biotherapeutics' Capital Expenditures (Quarter) stood at $636000.0 in 2023, then crashed by 89.94% to $64000.0 in 2024, then surged by 837.5% to $600000.0 in 2025.
  • Its Capital Expenditures was $600000.0 in Q3 2025, compared to $684000.0 in Q2 2025 and $882000.0 in Q1 2025.